Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant MAGE-3.1 antigen
- Development stage
- Phase 2
- Lead developer
- National Cancer Institute
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intradermal, Intravenous, Intramuscular
01
Overview
Recombinant MAGE-3.1 antigen is a tumor-specific melanoma-associated antigen produced using recombinant DNA technology. It is designed as a therapeutic cancer vaccine to stimulate the immune system to recognize and attack cells expressing the MAGE (Melanoma Antigen Gene) family proteins, particularly in melanoma and other tumors that express this antigen. Vaccination with recombinant MAGE-3.1 antigen aims to induce a host immune response against tumor cells bearing the MAGE-A family antigens, potentially leading to tumor regression or disease control[8][6]. The drug has been evaluated in clinical trials for its safety, immunogenicity, and anti-tumor activity in patients with advanced or metastatic melanoma[6]. Its mechanism of action involves presenting the specific tumor-associated peptide (MAGEA1) to the immune system, thereby promoting an anti-tumor T-cell response.
- Other names
- recombinant MAGE-3.1 antigen
02
Targets
MAGEA3 (Melanoma-associated antigen 3)MAGEA1 (Melanoma-associated antigen 1)
Beyond the preview
Go deeper on recombinant MAGE-3.1 antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant MAGE-3.1 antigen.